Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17342
Title: Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.
Authors: Martins, Ralph N;Villemagne, Victor;Sohrabi, Hamid R;Chatterjee, Pratishtha;Shah, Tejal M;Verdile, Giuseppe;Fraser, Paul;Taddei, Kevin;Gupta, Veer B;Rainey-Smith, Stephanie R;Hone, Eugene;Pedrini, Steve;Lim, Wei Ling;Martins, Ian;Frost, Shaun;Gupta, Sunil;O'Bryant, Sid;Rembach, Alan;Ames, David;Ellis, Kathryn;Fuller, Stephanie J;Brown, Belinda;Gardener, Samantha L;Fernando, Binosha;Bharadwaj, Prashant;Burnham, Samantha;Laws, Simon M;Barron, Anna M;Goozee, Kathryn;Wahjoepramono, Eka J;Asih, Prita R;Doecke, James D;Salvado, Olivier;Bush, Ashley I;Rowe, Christopher C;Gandy, Samuel E;Masters, Colin L
Affiliation: Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia
Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth WA, Australia
KaRa Institute of Neurological Diseases, Sydney NSW, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia
Cooperative Research Centre for Mental Health, Carlton, VIC, Australia
School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University of Technology, Bentley, WA, Australia
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, ON, Canada
CSIRO Australian e-Health Research Centre/Health and Biosecurity, Perth, WA, Australia
University of North Texas Health Science Centre, Fort Worth, TX, USA
National Ageing Research Institute, Parkville, VIC, Australia
University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, VIC, Australia
Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
School of Psychology and Exercise Science, Murdoch University, Perth, WA, Australia
eHealth, CSIRO Health and Biosecurity, Parkville, VIC, Australia
Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Issue Date: 2018
Citation: Journal of Alzheimer's disease : JAD 2018; 62(3): 965-992
Abstract: Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17342
DOI: 10.3233/JAD-171145
ORCID: 0000-0003-3910-2453
PubMed URL: 29562546
Type: Journal Article
Subjects: Alzheimer’s disease

amyloid
apolipoprotein E
biomarker
dementia
early diagnosis
preclinical
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.